Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Main Authors: | Jan Maurik van den Heuvel, Niloufar Farzan, Anke-Hilse Maitland-van der Zee, Fariba Ahmadizar |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-04-01
|
Series: | BMJ Open Diabetes Research & Care |
Online Access: | https://drc.bmj.com/content/8/1/e000705corr1.full |
Similar Items
-
Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands
by: Jan Maurik van den Heuvel, et al.
Published: (2020-04-01) -
Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
by: Ildiko Lingvay, et al.
Published: (2020-11-01) -
Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-07-01) -
Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Fang-Hong Shi, et al.
Published: (2018-06-01) -
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
by: Thomas Hansen, et al.
Published: (2020-12-01)